Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033775 | 1.00 | PPARA (0.58) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL3004720 | 1.00 | PPARA (0.58) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL1674845 | 0.95 | PPARA (0.54) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL14211452 | 0.91 | PPARA (0.57) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL4370045 | 0.91 | KLK5 (0.65) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL16286010 | 0.90 | CACNA1B (0.59) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL7965696 | 0.90 | PPARA (0.56) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL20481004 | 0.90 | CACNA1B (0.59) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL20144655 | 0.90 | CACNA1B (0.59) | PPARAKLK7KLK5SYKCTSS | |
| SCHEMBL7297130 | 0.90 | PPARA (0.56) | PPARAKLK7KLK5SYKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108264538-B | Solid Phase Synthesis Method of Aspartic Acid Condensate | 辽宁药联制药有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-12578345-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12379381-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120136674-A | Borneol derivative and application thereof in pharmacy | 浙江大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-119841819-A | Degradation agent for targeting BCR-ABL and application thereof | 北京大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20250059214-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-5317021-A | Analgesics, anticonvulsants | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5273982-A | An amidinoaryleneamidoalkylpiperazinyleneacetic acid | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5202340-A | Analgesics, anticonvulsants, anxiolytic agents, inhibitors for enkephalinases | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5194586-A | Adult T Cell Leukemia Associated Antigen | KURARAY CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0466944-A1 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUND AND ELASTASE INHIBITOR COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0423649-A1 | Peptides and use thereof | Kuraray Co., Ltd. (JP) | 1991-04-24 | — | — | EP | disclosed |
| US-4734400-A | BRONCHODILATION WITHOUT CARDIOVASCULAR SIDE EFFECTS | HOFFMANN-LA ROCHE INC. (US) | 1988-03-29 | — | — | US | disclosed |
| US-4629736-A | HIGH FIBRINOLYTIC ACTION; WATER SOLUBILITY; ANTICOAGULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-16 | — | — | US | disclosed |
| US-4605641-A | BRONCHODILATOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0136879-A2 | Fatty acid derivatives and processes of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12379381-B2 | Single molecule peptide sequencing | MICA, ANPEP, DNPEP | PPARA 3472/4885KLK7 1047/4885KLK5 3325/4885 |
| US-12578345-B2 | Single molecule peptide sequencing | SET, PTMS, MICA | PPARA 2576/4885KLK7 691/4885KLK5 2658/4885 |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | CYP21A2, CYP11B1, CYP11B2 | PPARA 864/4885KLK7 2738/4885KLK5 1541/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | PPARA 4669/4885KLK7 4274/4885KLK5 3488/4885 |
| US-20250059214-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, ACAT1, ACAA2 | PPARA 1372/4885KLK7 4446/4885KLK5 4114/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | PPARA 211/4885KLK7 2454/4885KLK5 1770/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PPARA 3215/4885KLK7 326/4885KLK5 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.